Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.69 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 4/20 | 0.53 |
| ▸ | HTR7 | P34969 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899230 | 0.82 | HTR6 (0.77) | HTR6HTR2AHTR2CHTR7DRD3 | |
| SCHEMBL3898702 | 0.82 | HTR6 (1.00) | HTR6HTR2AHTR2CHTR7 | |
| Hydrochloric Acid SCHEMBL3898962 | 0.81 | HTR6 (0.97) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3897408 | 0.80 | HTR6 (0.86) | HTR6HTR2AHTR2CHTR7DRD3 | |
| SCHEMBL13687088 | 0.79 | HTR6 (1.00) | HTR6HTR2AHTR2CHTR7DRD3 | |
| Hydrochloric Acid SCHEMBL3885084 | 0.78 | HTR6 (0.98) | HTR6HTR2AHTR2CHTR7DRD3 | |
| SCHEMBL13687071 | 0.76 | HTR6 (0.68) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL5784717 | 0.75 | HTR6 (0.63) | HTR6 | |
| SCHEMBL3887629 | 0.75 | HTR6 (0.68) | HTR6HTR2AHTR2CHTR7DRD3 | |
| SCHEMBL3887485 | 0.74 | HTR6 (0.80) | HTR6HTR2AHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585873-B2 | antiserotonine agents; central nervous system disorders; Alzheimer's disease; 3-(Phenylthio)-1H-pyrrolo[2,3-b]pyridine | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585873-B2 | antiserotonine agents; central nervous system disorders; Alzheimer's disease; 3-(Phenylthio)-1H-pyrrolo[2,3-b]pyridine | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1509522-B1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7074792-B2 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060148831-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-06 | — | — | US | disclosed |
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| US-6825212-B2 | SEROTONINE RECEPTORS ANTAGONIST; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148831-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR1A | HTR6 1/4885HTR2A 10/4885HTR2C 7/4885 |
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR1A | HTR6 1/4885HTR2A 10/4885HTR2C 7/4885 |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR3B | HTR6 1/4885HTR2A 11/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.